Covid-19 roundup: US to pay $725M for Eli Lilly's new mAb, if authorized; WHO chief scientist says more variants are coming
Eli Lilly had a big day in the Washington, DC area yesterday. After getting pummeled at an adcomm for submitting a cancer drug candidate with only Chinese trial data, the company and HHS announced later in the afternoon that the US would purchase 600,000 doses of the company’s next-gen monoclonal antibody to treat Covid-19 for at least $720 million.
But the doses of bebtelovimab, which will work against Omicron, will only be paid if the mAb is granted an EUA from the FDA. The mAb is currently in a Phase II trial and Lilly has submitted an EUA request for the treatment of mild to moderate Covid-19 in certain high-risk patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.